Clinical response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma. Black arrows denote ongoing treatment or follow-up. *Germline ALK variant. CR, complete response; PR partial response.
No takes yet. Share an insight, caveat, or question.
Ek et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: